

# ***FIRST ANNOUNCEMENT***

## **BBS Annual Meeting Federated learning and new data modalities**

**November 6, 2023, 13:00-17:30**

**Roche Auditorium, Grenzacherstrasse 124, Bau 92**

Access to large data marts will become more and more important for clinical development, but at the same time access to such data marts will be often restricted to access without transfer of data. Federated learning techniques help out here by allowing distributed analyses of such data marts. Federated learning will therefore have increased importance in the future for clinical development. Similarly, new data modalities like imaging or digital endpoints will become more important as well, serving as new endpoints or providing important information for enrichment and decision making. This BBS annual seminar is dedicated to these two topics and will provide an overview, case examples and the opportunity for discussion.

**Organizing committee:** Marisa Bacchi, Lilla Di Scala, Marc Vandemeulebroecke and Hans Ulrich Burger

### **Agenda**

- 13:00 – 13:10**      **Welcome**, Hans Ulrich Burger (Roche), BBS President
- 13:10 – 14:45**      **Federated Learning in clinical development**  
Chair: Marisa Bacchi (Janssen)  
- Marisa Bacchi: Short intro: Why federated learning in industry  
- Akexandros Giannakis (Accenture): Federated Learning – what is the art of the possible, the opportunities it creates, the key challenges and the prominent technical solutions  
- Anastasiia Koloskova (EPFL) Methodological aspects of federated learning, challenges and opportunities  
- Dominik Heinzmann (Roche): Collaborative acceleration for insights at scale via a federated data and biosample network in Neuroscience
- 14:45 – 15:15**      **Coffee break**
- 15:15 – 16:45**      **New data modalities: Impact of statistics**  
Chair: Marc Vandemeulebroecke (Novartis)  
- Laurent Essioux (Louis Pasteur institute, tbd) Overview on digital endpoints: Opportunities and impact on drug development  
- [Craig Wang](#) (Novartis): Radiogenomics investigation on the prognostic factors in metastatic breast cancer using data from Phase III ribociclib clinical trials  
- Stanislas Hubeaux (Roche): Opportunities and Challenges that arise with digital endpoints: A case example  
- Shyla Jagannatha (Janssen), Case example from Janssen on digital endpoints
- 16:45-17:15**      **Panel discussion for both sessions**  
Chair: Lilla Di Scala (Janssen)
- 17:15 – 17:30**      **Closure of the meeting**



### **Hybrid event:**

In person at Auditorium Bau 92, Roche, Basel, & virtual attendance

### **Participation is free of charge**

### **Registration**

Please register via the following [registration](#) link